Peptide vaccine for fibrolamellar liver cancer
Part of Cancer clinical trials.
This trial tests a patient-specific vaccine for people who have a rare type of liver cancer called fibrolamellar hepatocellular carcinoma (FL-HCC), or another cancer with the same genetic change. The vaccine is given after the cancer has been completely removed or treated, and it aims to teach your immune system to recognize and destroy any cancer cells that might be left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of cancer (fibrolamellar HCC or a related cancer) that has a particular genetic marker called 'DNAJB1-PRKACA'.
- Your cancer must be in complete remission, meaning it has been fully removed or treated and there is no sign of it right now.
- You must be at least 12 years old. If you are under 18, you need to weigh at least 40 kg (about 88 pounds).
- You should be in reasonably good health, able to do most daily activities, and have adequate blood counts and liver/kidney function.
- You must not be pregnant or breastfeeding, and if you can become pregnant (or your partner can), you need to use effective birth control during the study and for 3 months after the last vaccine dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
This study tests a new vaccine (a shot that may help your immune system attack cancer cells) combined with a glutamine-blocking drug (DRP-104) and two immunotherapy drugs (nivolumab and ipilimumab) for advanced fibrolamellar carcinoma. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
This trial tests a new mRNA vaccine for people with advanced liver cancer that has returned or spread after other treatments. The vaccine aims to help your immune system fight the cancer more effectively.
Hear when a new Fibrolamellar Hepatocellular Carcinoma (FLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.